RxDoctor Payments DataLook up a doctor →

Steven Elias, MD

Vascular Surgery · Englewood, NJNPI 1275587024

Payments from drug & device makers

$708,249in general payments, 2019–2025

Across 330 payments — averaging $2146.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$169K
  • Bard Peripheral Vascular, Inc.$127K
  • Biocompatibles, Inc.$107K
  • Philips North America LLC$91K
  • Medtronic$53K
  • Vesper Medical$37K
  • plus $125K from 15 others
$4,682in research payments, 2019–2025

Across 2 payments — averaging $2341.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Angiodynamics, Inc.$5K

What the payments were for

  • Consulting fees$326,17964%
  • Speaking & faculty fees$162,07432%
  • Grants$1,0000%
  • Travel & lodging$12,9183%
  • Food & beverage$7,0601%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$708,249 in reported general payments places this provider in the 95th percentile of 182 vascular surgery providers in New Jersey.

See all vascular surgery providers in New Jersey

Medicare billing

Part B allowed, 2024
$61,127
Medicare patients
256
Services billed
686

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban21$11,491
XareltoRivaroxaban12$6,450

Paid to pharmacies, not to this prescriber.

Other vascular surgery in Englewood

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →